News
Objective To evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumour activity of AMG 404, a fully human IgG1 monoclonal antibody targeting programmed cell death-1, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback